Sun Pharmaceutical Industries, Inc.
PharmaMumbai, India, India · Est. 1983 · 24,000 employees
Sun Pharmaceutical Industries is a global pharmaceutical company focused on generic medicines, specialty pharmaceuticals, and branded products across multiple therapeutic areas.
2
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
1
Indications↗
Distinct diseases across all programs
78
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
2 drugs in development
Phase 32
By Therapeutic Area
top 1
Immunology
2100%
R&D Momentum
27/100
Pipeline Velocity
19/100
Trial Completion Rate
93/100
Pipeline Concentration
100/100
Pipeline Freshness
76/100
Activity
Key Events
Nov 29, 2025TrialStudy of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
Nov 19, 2025TrialStudy of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
Aug 5, 2025TrialStudy to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Aug 4, 2025TrialA Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne Vulgaris
Dec 13, 2024FDAUNLOXCYT — UNLOXCYT
Jun 20, 2024TrialA Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris
May 13, 2024TrialA Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.
Dec 4, 2023TrialA Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.
4 more events
Aug 11, 2023TrialA Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.
Feb 22, 2023TrialA Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris
Oct 19, 2021TrialEuropean Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
Apr 16, 2021TrialA Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.
Details
Company Info
Company Overview
$9.5B
Mkt Cap
$4.8B
Revenue
—
Cash
CEODilip Shanghvi
Founded1983
Employees24,000
HQMumbai, India, India
Websitesunpharma.com
LinkedInCompany Page
Therapeutic Focus
Specialty pharmaceuticalsgeneric drugsophthalmologydermatology
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Immunology
Immunology
Regulatory
Regulatory Timeline
20181 event
FDAMar 20
Ilumya — ILUMYA
Application BLA761067 (BLA)
20241 event
FDADec 13
UNLOXCYT — UNLOXCYT
Application BLA761297 (BLA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)